These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 33765613)
1. Expression of PD-L1 in EBV-associated malignancies. Li X; Zhang W Int Immunopharmacol; 2021 Jun; 95():107553. PubMed ID: 33765613 [TBL] [Abstract][Full Text] [Related]
2. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1. Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721 [TBL] [Abstract][Full Text] [Related]
5. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma. Chiang NJ; Hou YC; Tan KT; Tsai HW; Lin YJ; Yeh YC; Chen LT; Hou YF; Chen MH; Shan YS Hepatol Int; 2022 Oct; 16(5):1137-1149. PubMed ID: 35780451 [TBL] [Abstract][Full Text] [Related]
6. [Current events in immunotherapy for upper aerodigestive tract cancer]. Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039 [TBL] [Abstract][Full Text] [Related]
7. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. Gullo I; Carvalho J; Martins D; Lemos D; Monteiro AR; Ferreira M; Das K; Tan P; Oliveira C; Carneiro F; Oliveira P Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018250 [TBL] [Abstract][Full Text] [Related]
8. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines. Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760 [TBL] [Abstract][Full Text] [Related]
9. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma. Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367 [TBL] [Abstract][Full Text] [Related]
10. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957 [TBL] [Abstract][Full Text] [Related]
11. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937 [TBL] [Abstract][Full Text] [Related]
12. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. Sasaki S; Nishikawa J; Sakai K; Iizasa H; Yoshiyama H; Yanagihara M; Shuto T; Shimokuri K; Kanda T; Suehiro Y; Yamasaki T; Sakaida I Gastric Cancer; 2019 May; 22(3):486-496. PubMed ID: 30264329 [TBL] [Abstract][Full Text] [Related]
13. PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability. Almhanna K; Antonia S J Natl Cancer Inst; 2018 Mar; 110(3):221-222. PubMed ID: 29155933 [No Abstract] [Full Text] [Related]
14. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Dai C; Geng R; Wang C; Wong A; Qing M; Hu J; Sun Y; Lo AW; Li J Mol Oncol; 2016 Dec; 10(10):1551-1558. PubMed ID: 27720576 [TBL] [Abstract][Full Text] [Related]
15. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068 [TBL] [Abstract][Full Text] [Related]
16. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2. Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276 [TBL] [Abstract][Full Text] [Related]
17. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786 [TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway. Cheng R; Li B; Wang H; Zeng Y Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Esophageal and Gastric Cancer. Kelly RJ Am Soc Clin Oncol Educ Book; 2017; 37():292-300. PubMed ID: 28561677 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]